• Skip to content
  • Skip to primary sidebar

Davis+Gilbert LLP

From our base in New York, we represent a diverse range of clients across the country and around the world.

  • People
  • Services
  • Emerging Issues

FTC

Two Websites Settle FTC Allegations That They Failed to Secure Consumer Data

May 21, 2019 by Keith Wewe

The Bottom Line The security of consumer data is an important priority for the FTC and has become even more important in recent years, particularly when such data is subject to attacks by malicious third parties. The FTC emphasized that both settlements contained “new requirements” going beyond Continue Reading

Alert - May 21, 2019

FTC and FDA Target Advertising of CBD Health Claims

May 17, 2019 by Catherine Nagle

The Bottom Line The legalization of hemp is a major step in establishing a potentially significant new industry. However, producers and marketers need to exercise caution when making health-related claims in connection with hemp-based product. The FTC and FDA will continue to aggressively review Continue Reading

Alert - May 17, 2019

FTC Settlement Over Charges of Misleading Consumer Reviews and Deceptive Negative Option Marketing Practices

May 10, 2019 by Catherine Nagle

The Bottom Line The FTC continues to take action where it finds that marketers are engaging in misleading incentivized product review practices or enrolling customers in deceptive “free trial” negative option plans without providing the appropriate disclosures and obtaining the consumer’s Continue Reading

Alert - May 10, 2019

FTC Plans Workshop on ‘Loot Boxes’

April 11, 2019 by Catherine Nagle

The Bottom Line A strong push has come forth from the likes of Senator Hassan, other legislators, the FTC and consumer lawsuits regarding consumer protection issues related to “loot boxes” in video games. This year may see efforts at regulating loot boxes move forward to the extent they have not Continue Reading

Alert - April 11, 2019

Video Social Networking App Agrees to Pay $5.7 Million to Settle FTC’s COPPA Action

March 25, 2019 by Catherine Nagle

The Bottom Line The sheer size of the Musical.ly settlement illustrates that the FTC continues to have a strong interest in enforcing COPPA. Online services cannot hide behind language in their terms and conditions claiming not to be child-directed when they include numerous activities that Continue Reading

Alert - March 25, 2019

FTC Brings First Action Against Company for Posting Fake Reviews

March 12, 2019 by Catherine Nagle

The Bottom Line It should come as no surprise to companies that they should not be purchasing or posting fake reviews of their products as a way to improve sales to customers. The action against Cure Encapsulations and its owner shows that the FTC is interested in taking action to halt the Continue Reading

Alert - March 12, 2019

FTC and FDA Sent Warning Letters to Companies Advertising Products that Claim Treatment of Disease

March 7, 2019 by Catherine Nagle

The Bottom Line The FTC and FDA are aggressively reviewing companies’ websites and social media channels for false or unsubstantiated health claims and efficacy claims. Advertisements on company websites and in social media posts must avoid false or unsubstantiated health claims, and efficacy Continue Reading

Alert - March 7, 2019

New York and Florida AGs Settle Charges with Seller of Fake Social Media Accounts and Engagements

February 13, 2019 by Catherine Nagle

The Bottom Line Brands, marketers, and their agencies typically have the most to lose due to fraudulent social media traffic, in the form of wasted marketing dollars spent appealing to non-existent users. However, these settlements made clear that such practices also harm consumers and social Continue Reading

Alert - February 13, 2019

Mastercard Announces New Free Trial Rules for Merchants

February 6, 2019 by Catherine Nagle

The Bottom Line Companies that engage in negative option and subscription-based marketing must comply with various federal and state laws governing their practices. The proposed Mastercard rules will add another set of requirements to this compliance landscape. Marketers should prepare to comply Continue Reading

Alert - February 6, 2019

The FTC’s “Reasonable Basis” Standard Has Evolved for Disease Efficacy Claims

January 9, 2019 by Catherine Nagle

The Bottom Line The FTC made it clear many times in 2018 that disease efficacy claims must be supported by competent and reliable scientific evidence, including human clinical testing, and that expert opinions will help guide the kind of human clinical testing and the number of RCTs that is Continue Reading

Alert - January 9, 2019

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Interim pages omitted …
  • Page 15
  • Go to Next Page »

Primary Sidebar

  • Sitemap
  • Privacy Policy
  • Terms and Conditions
  • Accessibility Statement
  • About Us
  • Location
  • Subscribe
© 2025 Copyright Davis+Gilbert LLP. Attorney Advertising.
  • People
  • Services
  • Emerging Issues
  • Insights + Events
  • Culture + Community
  • Pro Bono + Corporate Social Responsibility
  • Careers
  • About Us
  • Subscribe
  • Location
This site uses cookies from third party providers for them to collect and store information from and on your device. These cookies either support essential functions of the site or are used to develop analytics regarding usage of our site. Click Accept to continue using the site with our recommended settings or click Decline to disable non-essential cookies. See our Privacy Policy for more information.AcceptDeclinePrivacy policy